Garuda - Garba Rujukan Digital

Article Per Year (5 Year)

All

Indonesian Journal of Cancer

ijoc
Website

Published by National Cancer Center-Dharmais Cancer Hospital

ISSN : 19783744 EISSN : 23556811 DOI : https://www.doi.org/ 10.33371

Core Subject : Health, Science,

Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health

Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.

Arjuna Subject : Kedokteran - Onkologi

Articles 562 Documents

31 32 33 34 35

Cryotherapy as A Prophylaxis of Mucositis in Children with Cancer Undergoing Chemotherapy at Dr. M. Djamil General Hospital Hidayatul Hasni; Mayetti Mayetti; Dwi Novrianda
Indonesian Journal of Cancer Vol 15, No 4 (2021): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Mucositis is one of the side effects of chemotherapy, which can be a severe problem for children with cancer. Cryotherapy can cause vasoconstriction and decrease blood flow to the oral mucosa, resulting in lower concentrations of chemotherapy agents to prevent mucositis. This study aims at determining the effectiveness of oral cryotherapy as prophylaxis mucositis in children with cancer undergoing chemotherapy.Methods: This quasi-experiment study with a pretest-posttest control-group design involved 45 respondents (22 in the intervention group and 23 in the control group) selected using consecutive sampling. The data collection instrument was the WHO mucositis scale. Results: Of the 45 children undergoing chemotherapy, 24 (53.3%) were of school age, 25 (55.6%) were male, 33 (73.3%) had good nutritional status, and 17 (37.8%) had mild neutropenia before undergoing chemotherapy. All respondents (100%) did not experience mucositis, but after chemotherapy, 9 children (40.9%) in the intervention group had mucositis, and 19 children (82.6%) experienced mucositis in the control group. The data were analyzed using the Wilcoxon test to see the difference between the intervention group and the control group and the Chi-Square test with Yates’s correction to see the effect of cryotherapy on the prevention of mucositis. The results showed that there was a difference in the incidence of mucositis between before and after intervention in the intervention group (p = 0.003) and the control group (p = 0.000), and cryotherapy was effective in preventing mucositis (p = 0.01).Conclusions: Cryotherapy is effective against the prevention of mucositis. Nurses and families need to be able to apply oral cryotherapy and other evidence-based treatment as a method to prevent mucositis

Profile of Nasopharyngeal Cancer Patients who Underwent Radiotherapy in Dr. Hasan Sadikin General Hospital Bandung Indira Meidina Nafisa; Marhendra Satria Utama; Mas Adi Sunardi; Antony Abel Adibrata
Indonesian Journal of Cancer Vol 16, No 2 (2022): June
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Nasopharyngeal cancer (NPC) is a malignant epithelial tumor located in the nasopharynx and is the most common head and neck malignancy. This study aimed to find and describe the profile of NPC patients who undergo radiotherapy at Dr. Hasan Sadikin General Hospital, Bandung.Methods: This study was a descriptive study conducted at the Department of Radiology of Dr. Hasan Sadikin General Hospital, Bandung. This study employed a total sampling method and was done by observing patients’ status/medical records from January 1, 2018, to December 31, 2019, which was registered based on the Hospital-Based Cancer Registry (HBCR). The inclusion criteria were all patients diagnosed with NPC and undergone radiotherapy.Results: There were 274 records (19.74%) included as NPC from 1,388 records. This cancer was more frequent in men (70.4%), in the age group of 45–54 years (35.0%), non-active smokers (58.8%), entrepreneurs (23.0%), and those who came from West Priangan (36.1%). The most common chief complaint was an enlargement of neck lymph nodes (55.1%) at stage IVB (42.8%). Histopathological findings were dominated by undifferentiated squamous cell carcinoma (WHO III) (74.4%). Most of the patients were treated with chemoradiation (64.3%).Conclusions: NPC could happen to anyone with different background. This study found it was more frequent in men than women (2.3:1), in the fourth and fifth decade of life, in entrepreneurs followed by housewives, and even in non-active smokers. It also could happen in children to the elderly. Most patients came with an enlargement of neck lymph nodes as their chief complaint in the advanced stage and need chemoradiation as their treatment.

Analisis Hambatan Siklus Sel Kanker Lidah Manusia SP-C1 yang Diinduksi oleh Biskoklaurin Alkaloid Cepharantine Menggunakan flow cytometry SUPRIATNO -
Indonesian Journal of Cancer Vol 4, No 3 (2010): Jul - Sep 2010
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v4i3.103

Flow cytometry has been widely used for detecting of apoptosis and cell cycle arrest on several human cancer cells. Supris clone-1 (SP-C1) cell is an oral tongue squamous cell carcinoma cell line which has rapidly growth, highly migration-invasion and metastatic to regional and distant lymph nodes. The aim of the study was to analyze the cell cycle arrest of SP-C1 inducted by cepharantine (CE) using flow cytometry. Treatment of SP-C1 cells with CE concentration 0, 5, 10 and 20 g/ml was carried out for 72 hours. The examination of cell cycle arrest of SP-C1 by flow cytometry revealed that CE with concentration 10 and 20 g/ml was significantly arrested of SP-C1 cell cycle in G1-S phase. Moreover, apoptosis was detected in G0 phase on the cells treated by CE 20 g/ml. These results concluded that CE had a potency to increase apoptosis with suppressing SP-C1 cell cycle phases.

Profil Penderita Karsinoma Tiroid di RSUP dr. Kariadi, Semarang (Januari 2006 Juni 2010) YAN WISNU PRAJOKO
Indonesian Journal of Cancer Vol 7, No 4 (2013): Oct - Dec 2013
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14414/ijoc.v7i4.307

Penelitian ini bertujuan mengidentifikasi insiden dan pola kejadian kanker tiroid di RS Dr. Kariadi periode Januari 2006 Juni 2010. Penelitian deskriptif ini dilakukan terhadap 318 pasien yang dirawat dengan diagnosis Malignant Neoplasma of Thyroid (ICD-10 C73). Pengamatan dilakukan terhadap usia, jenis kelamin, histopatologi, ukuran tumor (T), metastasis KGB (N), metastasis jauh (M), tempat tinggal, dan komorbid. Sebanyak 29 pasien dieksklusi karena data tidak lengkap. Didapatkan 221 pasien perempuan (76,5%); usia tersering 20-50 tahun (56,1%); T3 sebanyak 31,8%; tidak terdapat metastasis KGB dan metastasis jauh 54,7% dan 86,5%; adenokarsinoma papiler 61,2%. Sebanyak 86,9% tinggal di ketinggian <50 m di atas permukaan laut. Hanya 39 penderita yang mengalami gangguan sesak napas. Kesimpulan, kanker tiroid masih menjadi masalah dalam penanganan kasus keganasan, karena jumlah kasus yang relatif masih tinggi dan pada umumnya penderita datang dalam kondisi penyakit yang lebih lanjut. Penanganan yang cepat dan tepat sejak diagnosis, baik klinis maupun patologis, hingga tahap terapi harus dapat dilakukan oleh ahli bedah dengan baik, sehingga dapat diperoleh hasil yang memuaskan.Kata Kunci: karsinoma tiroid, insidensi, faktor risiko

Ekspresi CD44 (Penanda Sel Punca Kanker) sebagai Faktor Prognostik Kekambuhan pada Kanker Ovarium Tipe Epitel Stadium III PUNGKY MULAWARDHANA; INDRA YULIATI; KETUT SUDIANA
Indonesian Journal of Cancer Vol 11, No 3 (2017): July - September 2017
Publisher : National Cancer Center - Dharmais Cancer Hospital

Epithelial ovarian cancer is a deadly cancer, cancer recurrence and resistance post surgical staging and chemotherapy are major problems which will eventually occur in most advanced stage ovarian cancer. Recent investigations have unravelled the role of CSC/ Cancer Stem Cell in the cancer recurrence and therapy resistance, CD44 has been reported as a CSC marker in ovarian cancer, investigator wanted to analyse CD44 expression as recurrence prognostic factor in stage III epithelial ovarian cancer. Purpose: to analyse the role of CD44 expression as recurrence prognostic factor in stage III epithelial ovarian cancer. Metode: Hystorical Cohort, ICH CD44 examination was performed on the pathological ovarian cancer sample which diagnosed with platinum resistant recurrence (study sample) and platinum sensitive recurrence (control sample). CD44 expression was measured, the role as recurrence prognostic factor evaluated, influence of CD44 expression increasetowards earlier recurrence analysed, and the CD44 expression differences between 2 groups based on grade; pathological type; and stadium were measured and analysed. Results: 40 research subjects were involved in the research, with 20 among them were platinum resistant and the other 20 were platinum sensitive. Mean CD44 expression in the platinum resistant group was 36,80+29,54; while in the resistant platinum was 7,05+9,58. There was a significant difference of CD44 expression between 2 groups (p=0,000). There was a strong correlation between CD44 expression with the timing of recurrence (p=0,894). With the cut off of12,5; 85% platinum resistant subject had CD44>12,5; 85% platinum sensitive subject had CD44<12,5; with 85% sensitivity and 85% specificity as a good recurrence prognostic factor. Relative Risk (RR) of CD44 Expression is 5,667, RRof tumor residue post surgical staging is 2,513. Through logistic regression analysis, it was concluded that high expression of CD44 and tumor residue are risk factors for recurrences, patient with CD44 expression of ≥ 12,50 has possibility of earlier recurrence (< 6 months) 48,487 times compared with patient with CD44 expression of < 12,50 and patient with tumor residue of < 1cm has possibility of earlier recurrence 13,013 times compared with patient without macroscopic residue.Conclusion: This research found that CD44 expression can be used as recurrence prognostic factor in stage III epithelial ovarian cancer, CD44 expression was significantly higher in the platinum resistant group, there was negative correlationbetween CD44 expression with the timing of recurrence. CD44 expression as recurrence prognostic factor was not influenced with grade and pathologic type, but influenced by stage. Expression of CD44 and tumor residue post surgical staging are good predictors for recurrence timing.ABSTRAKKanker ovarium tipe epitel adalah suatu kanker yang mematikan. Kekambuhan dan resistansi kanker pasca-surgical staging dan kemoterapi merupakan masalah utama yang akan terjadi pada sebagian besar kanker ovarium stadium lanjut. Penelitian-penelitian terbaru mengemukakan peran CSC (Cancer Stem Cell) dalam proses kekambuhan dan resistansi terapi. CD44 telah dilaporkan sebagai marker CSC pada kanker ovarium. Peneliti ingin meneliti ekspresi CD44 sebagai faktor prognostik kekambuhan kanker ovarium tipe epitel stadium III. Penelitian ini bertujuan menganalisis peran ekspresi CD44 sebagai faktor prognostik kekambuhan pada kanker ovarium tipe epitel stadium III. Metode yang digunakan dalam penelitian ini adalah hystorical cohort, di mana dilakukan pemeriksaan IHC CD44 pada sampel PA pasien kanker ovarium yang mengalami kekambuhan resistan platinum (sampel studi) dan sensitif platinum (sampel pembanding). Ekspresi CD44 diukur, peran sebagai faktor prognostik kekambuhan dievaluasi, pengaruh peningkatan ekspresi CD44 pada kekambuhan yang lebih dini dianalisis, dan perbedaan ekspresi CD44 dinilai pada 2 kelompok berdasarkan grade, tipe PA, dan stadium. Sebanyak 40 subjek penelitian dengan rincian 20 kelompok resistan platinum dan 20 kelompok sensitif platinum diikutkan dalam penelitian ini. Rerata ekspresi CD44 pada kelompok resistan adalah 36,80+29,54 dan kelompok sensitif platinum 7,05+9,58. Didapatkan perbedaan signifikan ekspresi CD44 di antara dua kelompok (p=0,000). Didapatkan pula hubungan yang kuat antara ekspresi CD44 dengan waktu kekambuhan (p=0,894). Dengan cut off 12,5; 85% sampel resistan platinum memiliki CD44>12,5 dan 85% sampel sensitif platinum memiliki CD44<12,5 dengan sensitivitas 85% dan spesifisitas 85% sebagai faktor prognostik kekambuhan yang baik. Didapatkan RR ekspresi CD44 sebesar 5,667, RR residu tumor pasca-surgical staging sebesar 2,513. Melalui analisis regresi logistik, didapatkan bahwa ekspresi CD44 yang tinggi dan adanya residu merupakan faktor risiko kekambuhan. Penderita dengan ekspresi CD44 ≥ 12,50 berisiko kambuh <6 bulan sebesar 48,487 kali penderita dengan ekspresi CD44 < 12,50; dan penderita dengan residu < 1 cm berisiko kambuh <6 bulan sebesar 13,013 kali penderita tanpa residu makroskopik. Penelitian ini menyimpulkan bahwa ekspresi CD44 dapat dipakai sebagai faktor prognostik kekambuhan pada kanker ovarium tipe epitel stadium III, ekspresi CD44 secara signifikan lebih tinggi pada kelompok resistan platinum, serta ada hubungan negatif antara ekspresi CD44 dengan waktu terjadinya kekambuhan. Ekspresi CD44 sebagai faktor prognostik tidak dipengaruhi oleh grade dan tipe PA, tetapi dipengaruhi oleh stadium kanker. Ekspresi CD44 dan residu tumor pasca-surgical staging merupakan indikator prediktif yang baik untuk kecepatan kekambuhan.

Determinants of Human Papilloma Virus (HPV) Vaccination among Elementary Students in Central Jakarta Febrianti, Rini; Wahidin, Mugi
Indonesian Journal of Cancer Vol 15, No 1 (2021): March
Publisher : http://dharmais.co.id/

Background: Human Papilloma Virus (HPV) is the leading risk factor of cervical cancer. World Health Organization (WHO) has recommended including HPV vaccination in national immunization programs in all countries. Specifically, Jakarta Province has been implementing HPV vaccination since 2016. In this case, several factors influence vaccination coverage. However, there is limited evidence about determinants associated with HPV vaccination. Therefore, this study aimed to investigate the factors associated with HPV vaccination among elementary students in Central Jakarta.Methods: This was a cross-sectional study conducted from March until June 2020. The study population involved 167 female students of the 6th level of the elementary school in Central Jakarta. There were eight elementary schools in Kemayoran and Cempaka Putih Sub Districts selected purposively. Primary data was collected employing an online questionnaire, which was fulfilled by respondents (mothers and students). Data were analyzed utilizing statistic software for descriptive and bivariate analysis. For the bivariate analysis, Chi-Square Test was performed.Results: The HPV vaccination coverage was 80.84%. It was also showed that the last education level of the respondents’ father and mother was mainly senior high school (SMA) for 50.3% and 47.9%, respectively. The mothers’ knowledge was mainly in the middle (56.9%), and they had a positive attitude/support (67.1%). There were only 2.4% of the respondents with a family history of cervical cancer. In terms of family economic status, the main part of respondents had low expenditure for 2-3 million IDR (59.3%) a month. Meanwhile, human resources (vaccination providers) and HPV vaccine were 100% available in the vaccination service. Of the respondent, 47.9% of those said that the vaccine price was affordable. Children who had no support to get HPV vaccination from their father, mother, and siblings were 14.4%, 6.6%, and 21.6%, respectively. Besides, children who were not supported by their teachers was 3.6% and not supported by their peers was 23.4%. Meanwhile, father and mother’s supports were significantly associated with HPV vaccination.Conclusions: Factors associated with HPV vaccination were the support from the father and mother.

Gambaran Mikrobiologi pada Ruang Isolasi Imunitas Menurun dan Ruang Operasi (Studi di Rumah Sakit Kanker “Dharmais” Jakarta, 2013-2014) NI PUTU ARYADNYANI; EVA AYU MAHARANI; DEWI ASTUTI; DEMAK LUMBAN TOBING
Indonesian Journal of Cancer Vol 10, No 2 (2016): April - June 2016
Publisher : National Cancer Center - Dharmais Cancer Hospital

ABSTRACTPatients treated at the ward in a hospital can get nosocomial infection through exposure of microbes that contaminate air and medical equipments. This study was conducted to determine the amount of air microbes and to identify bacterium found on a swab equipments at Isolation room on decrease immunity and operating theatre in “Dharmais” Cancer Hospital Jakarta. This study uses secondary data on a periode of 2013-2014. The amount of microbial colonies that meet the threshold value in accordance with a predetermined on Kepmenkes RI No. 1204 / Menkes / SK / X / 2004 on a Hospital Environmental Health Requirements in RIIM is at 100%, while at OK is 13:33%. Types of microbes found in the RIIM were E. gergoviae, A. baumanni, S. liquefaciens, C. freundii, Y. enterocolitica, C. diversus and fungi while the types of microbes found in the OK room were A. haemolyticus, M. morganii, A. baumanni, E. coli, A. Iwoffli, K. oxytoca, C. diversus, K. ozaenae, P. stuartii, S. marcescens, Y. enterocolitica, and fungi. ABSTRAKPasien yang dirawat di ruang rawat inap sebuah rumah sakit bisa mendapat infeksi nosokomial melalui paparan dengan mikroba udara maupun yang mengontaminasi peralatan medis. Penelitian ini dilakukan untuk mengetahui jumlah koloni mikroba udara dan identifikasi bakteri pada swab peralatan di Ruang Isolasi Imunitas Menurun (RIIM) dan ruang operasi (OK) di RS Kanker “Dharmais”, Jakarta. Penelitian ini menggunakan data sekunder periode 2013-2014. Jumlah koloni mikroba yang memenuhi nilai ambang batas sesuai dengan yang telah ditetapkan pada Kepmenkes RI nomor 1204/Menkes/SK/X/2004 tentang Persyaratan Kesehatan Lingkungan Rumah Sakit pada RIIM adalah sebesar 100%, sedangkan pada OK sebesar 13,33%. Jenis mikroba yang ditemukan pada ruang RIIM adalah E. gergoviae, A. baumanni, S. liquefaciens, C. freundii, Y. enterocolitica, C. Diversus, dan jamur, sedangkan jenis mikroba yang ditemukan pada ruang operasi adalah A. haemolyticus, M. morganii, A. baumanni, E.coli, A. Iwoffli, K. oxytoca, C. diversus, K. ozaenae, P. stuartii, S. marcescens, Y. enterocolitica, dan jamur.

Profile of Radiation Therapy after Radical Prostatectomy: Experience in a Tertiary Hospital in Jakarta, Indonesia Rama Firmanto; Agus Rizal AH Hamid; Chaidir Arif Mochtar; Rainy Umbas
Indonesian Journal of Cancer Vol 14, No 1 (2020): March
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Despite the high recurrence rate, radical prostatectomy (RP) remains as a preferable surgical treatment of localized prostate cancer. Adjuvant radiotherapy (ART) and salvage radiotherapy (SRT) are available approaches in preventing biochemical progression after RP. We aim to investigate the use of radiotherapy, both ART and SRT, in those who underwent RP.Methods: We used a retrospective cohort study design, with samples recruited from prostate cancer patients who underwent RP between January 2008 and December 2016. Patients who had undergone RP at Cipto Mangunkusumo Hospital, Jakarta, Indonesia were included in the present study. More in detail, three and five subjects were treated with ART and SRT, respectively. We only included those who had a minimum of one year of follow-up. Variables including age, preoperative prostate-specific antigen (PSA), clinical staging, pathological staging, Gleason score, and death were recorded. We analyzed the overall survival time using the Kaplan-Meier method.Results: From 34 patients included in the study, 26 underwent RP alone, while 5 patients underwent adjuvant radiotherapy and 3 patients underwent salvage radiotherapy after RP. The mean ages in the three groups were 61.46 ± 5.76, 58.2 ± 4.86 and 62.67 ± 7.5, respectively. The preoperative PSA value was above 10 mg/dL in 61.5% in patients without RT, 100% in patients with ART after RP, and none in SRT. 17 (51.5%) out of 33 subjects were ≥T2 clinical stage and 24/30 (80%) subjects were ≥pT2. Timing for ART and SRT ranged from 1.07 to 6.3 and 5.27 to 21.43 months after RP, respectively. The 10-year survival rates were 84.6% in patients with RP alone, 80% in patients with ART+RP, and 66.7% in patients with SRT+RP. The average survivals of those who had RP alone as well as ART and SRT were 44.56 ± 32.64, 46.79 ± 24.02, and 71.71 ± 38.74 months.Conclusions: The average survival of those who received SRT is better than those who underwent ART and RP alone. Prospective studies with larger samples are needed to evaluate the efficacy of radiation therapy after radical prostatectomy.

Prostatektomi Radikal: Morbiditas dan Mortalitas di RSUP dr. Hasan Sadikin, Bandung Ferry Safriadi
Indonesian Journal of Cancer Vol 7, No 1 (2013): Jan - Mar 2013
Publisher : National Cancer Center - Dharmais Cancer Hospital

Kanker prostat merupakan salah satu jenis keganasan tersering pada pria. Prostatektomi radikal merupakan terapi pilihan pada kanker prostat yang masih organ confined. Tindakan ini merupakan tindakan operatif dengan derajat kesulitan tinggi, sehingga risiko morbiditas atau mortalitas harus menjadi perhatian. Tujuan penelitian ini adalah mengevaluasi morbiditas, mortalitas pasien, dan faktor yang berperan.Penelitian ini dilakukan secara retrospektif dengan mengumpulkan data dari rekam medis dan status khusus pasien kanker prostat yang telah menjalani operasi prostatektomi radikal dari 2005 sampai 2011 di RS Hasan Sadikin. Analisis univariat dilakukan dengan Chi-square untuk menilai faktor yang berperan terhadap morbiditas dan mortalitas.Sebanyak 90 pasien sebagai subjek penelitian. Usia rerata subjek 62,99 + 5,32 tahun, nilai PSA 31,89 + 29,13 ng/ml, volume prostat 53,24 + 29,13 ml, skor Gleason paling banyak ditemukan pada rentang 2-6 sebesar 58,9%. Rerata lama operasi 236,74 + 89,78 menit dengan jumlah perdarahan sebanyak 874,22 + 573,46 ml dan transfusi 318,11 ml.Morbiditas mayor ditemukan pada 8 kasus (0,08%); 6 kasus termasuk klasifikasi modikasi Clavien derajat 3 dan 2 kasus derajat 5. Analisis statistik tidak menunjukkan adanya kaitan antara usia, PSA, volume prostat, skor Gleason, dan stadium T terhadap terjadinya morbiditas dan mortalitas.Kesimpulannya, morbiditas pada penelitian ini sebesar 0,06% dan mortalitas 0,02%. Faktor usia, PSA, volume prostat, skor Gleason, dan stadium T tidak bermakna secara statistik. Penapisan pra-operasi yang baik akan mencegah terjadinya morbiditas dan mortalitas, selain faktor pengalaman operator.Kata kunci: kanker prostat, prostatektomi radikal, morbiditas, mortalitas.

Efficacy and Safety of In-Asia-Manufactured rhG-CSF 300 mcg As Primary Prophylaxis for Prevention of CHOP Chemotherapy-induced Severe Neutropenia in Elderly Patients with Lymphoma Non-Hodgkin Harryanto Reksodiputro; Zubairi Djoerban; Karmel L. Tambunan; Aru W. Sudoyo; Abidin Widjanarko; Djumhana Atmakusuma; Syafrizal Syafei; Nugroho Prayogo; Ronald Hukom; Dody Ranuhardy; Zakifman Jack; Asrul Harsal; Noorwati S -; Bambang Karsono; Shufrie Effendi; Hilman Tadjoedin
Indonesian Journal of Cancer Vol 3, No 1 (2009): Jan - Mar 2009
Publisher : National Cancer Center - Dharmais Cancer Hospital

Penelitian open-label, non-komparatif ini dilakukan untuk mengevaluasi efektivitas dan keamanan recombinant human G-CSF produksi Asia sebagai profilaksis primer dalam pencegahan neutropenia derajat berat pada pasien usia lanjut (>60 tahun) dengan limfoma non-Hodgkin (LNH) derajat sedang dan lanjut (stadium II,III,IV) yang mendapat terapi CHOP (siklofosfamid, doksorubisin, vinkristin). Profilaksis primer recombinant human G-CSF (rhG-CSF) produksi Asia dapat mengurangi median durasi neutropenia derajat 4 pada siklus sitostatistika ke-1 dan ke-2 menjadi tiga hari, sementara median durasi neutropenia derajat 3 pada siklus sitostistika ke-1 menjadi dua hari dan pada siklus sitostatistika ke-2 menjadi dua setengah hari, dari median durasi neutropenia grade 4 dan grade 3 tanpa G-CSF, yaitu empat dan lima hari berurutan. Febrile neutropenia ditemukan pada 7 pasien yang mendapat rhG-CSF produksi Asia (24.1%), lebih rendah jika dibandingkan studi tanpa rhG-CFS (31.3-34% FN). Tiga pasien mendapat rhG-CSF produksi Asia (10,3%) dirawat inap akibat febrile neutropenia, lebih rendah jika dibandingkan rawat inap pada studi tanpa rhG-CSF (24-28%). Kejadian yang tidak diinginkan terbanyak adalah mual dan muntah yang terjadi pada 9 (31%) pasien. Sebagai kesimpulan, penggunaan rhG-CSF produksi Asia untuk profilaksis primer pada pasien LNH usia lanjut yang mendapat regimen CHOP dapat mengurangi durasi neutropenia, mengurangi kejadian febrile neutropenia, dan angka rawat inap akibat febrile neutropenia.Kata kunci : Efektivitas, keamanan, G-CSF, LNH pada usia lanjut

Page 33 of 57 | Total Record : 562

31 32 33 34 35

Filter by Year

2007 2025

Filter By Issues

All Issue Vol 19, No 3 (2025): September Vol 19, No 2 (2025): June Vol 19, No 1 (2025): March Vol 18, No 4 (2024): December Vol 18, No 3 (2024): September Vol 18, No 2 (2024): June Vol 18, No 1 (2024): March Vol 17, No 4 (2023): December Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name Bayu Brahma

Contact Email journal.cancer@gmail.com

Phone +628176389956

Journal Mail Official admin@indonesianjournalofcancer.or.id

Editorial Address National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location Kota adm. jakarta barat, Dki jakarta INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA